trending Market Intelligence /marketintelligence/en/news-insights/trending/5u_2nzbzAvo611ITF4LI-A2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Paris court rules against Onxeo in SpePharm, SpeBio dispute

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Paris court rules against Onxeo in SpePharm, SpeBio dispute

The Commercial Court of Paris ruled against Onxeo SA in its dispute with SpePharm and their 50-50 joint venture SpeBio BV.

SpeBio BV was formed to distribute Loramyc for the treatment of oropharyngeal candidiasis, a yeast/fungal infection.

The court directed Onxeo to pay SpePharm and SpeBio €50,000 and €8.6 million in damages, respectively. SpePharm and SpeBio will also receive procedural indemnities of €15,000 and €250,000, respectively.

Onxeo said it will contest the decision.

The dispute, which Onxeo started in 2009, involves alleged contract breaches by SpePharm and SpeBio that resulted in a delay in the marketing and sales of Loramyc.

Onxeo was formerly known as BioAlliance Pharma.